Maternal serum ADAMTS-9 levels in gestational diabetes: a pilot study

Simple item page
dc.contributor.authorArtunc-Ulkumen B.
dc.contributor.authorUlucay S.
dc.contributor.authorPala H.G.
dc.contributor.authorCam S.
dc.date.accessioned2024-07-22T08:10:41Z
dc.date.available2024-07-22T08:10:41Z
dc.date.issued2017
dc.description.abstractObjective: Gestational diabetes mellitus (GDM) is characterized with insulin resistance which is diagnosed during pregnancy. Although pregnancy is a diabetogenic state, not all women develop GDM. Genetic factors together with enviromental factors cause the maladaptation of maternal pancreas to this diabetogenic state and GDM develops. ADAMTS-9 is a recently recognized molecule whose genetic variants have risk of GDM. Decreased levels have already been shown in fetal membranes. Maternal serum levels of this protein have not been studied yet. We hypothesized that the alteration of ADAMTS-9 expression should cause changes in maternal serum levels which further could help to identify the disease and develop new treatment strategies. Materials and methods: This prospective case–control study is consisted of 27 pregnancies with GDM and 30 healthy singleton pregnancies matched for matenal age, gestational week, and maternal weight. GDM diagnosis was made with 2-h 75 g oral glucose tolerance test. ADAMTS-9 levels were compared between groups. Results: ADAMTS levels were 3.62 ± 0.33 ng/dL (range: 3.04–4.23) in GDM group and 4.65 ± 1.70 ng/dL (range: 3.07–8.21) in control group (p < 0.001). ADAMTS levels were not affected by maternal age, gestational age, and maternal weight. Conclusion: ADAMTS-9 levels were significantly lower in GDM pregnancies. This may help to understand the mechanism of GDM pathogenesis. In future, target treatments with ADAMTS proteins may help to improve the severity of diabetes pathogenesis. © 2016 Informa UK Limited, trading as Taylor & Francis Group.
dc.identifier.DOI-ID10.1080/14767058.2016.1219717
dc.identifier.issn14767058
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/15349
dc.language.isoEnglish
dc.publisherTaylor and Francis Ltd
dc.subjectADAMTS9 Protein
dc.subjectAdult
dc.subjectCase-Control Studies
dc.subjectDiabetes, Gestational
dc.subjectFemale
dc.subjectGlucose Tolerance Test
dc.subjectHumans
dc.subjectPilot Projects
dc.subjectPregnancy
dc.subjectProspective Studies
dc.subjectRisk Factors
dc.subjectADAMTS9 protein
dc.subjectADAMTS9 protein
dc.subjectADAMTS9 protein, human
dc.subjectadult
dc.subjectanalysis of variance
dc.subjectangiogenesis
dc.subjectArticle
dc.subjectcase control study
dc.subjectclinical article
dc.subjectclinical feature
dc.subjectcontrolled study
dc.subjectcorrelation analysis
dc.subjectdemography
dc.subjectdiastolic blood pressure
dc.subjectenzyme linked immunosorbent assay
dc.subjectfemale
dc.subjectgenetic predisposition
dc.subjectgestational age
dc.subjectglucose blood level
dc.subjectheredity
dc.subjecthuman
dc.subjectinsulin resistance
dc.subjectmaladjustment
dc.subjectmaternal serum
dc.subjectmiddle aged
dc.subjectnutritional intolerance
dc.subjectoral glucose tolerance test
dc.subjectoutpatient department
dc.subjectpilot study
dc.subjectpregnancy diabetes mellitus
dc.subjectpriority journal
dc.subjectprospective study
dc.subjectprotein expression
dc.subjectsystolic blood pressure
dc.subjectyoung adult
dc.subjectblood
dc.subjectglucose tolerance test
dc.subjectmetabolism
dc.subjectpilot study
dc.subjectpregnancy
dc.subjectpregnancy diabetes mellitus
dc.subjectrisk factor
dc.titleMaternal serum ADAMTS-9 levels in gestational diabetes: a pilot study
dc.typeArticle

Files

Collections

Scopus Koleksiyonu